Therapeutic Drug Monitoring

Therapeutic Drug Monitoring

Clinicians need to know if patients are receiving enough drug for an appropriate amount of time to ensure the best outcomes. This is especially important in critically ill and children because of the pharmacokinetics and pharmacodynamics of these patient groups.

We are developing methods to enable therapeutic drug monitoring (TDM) in high-risk patient populations. In TDM, drug concentrations are measured in patient blood samples. These measurements help ensure proper dosing and improve understanding of the correlation between drug exposure and treatment outcomes. Currently, TDM normally requires sending patient blood samples to external reference labs for analysis, which is slow and costly. Our research involves developing rapid, simple methods that enable TDM near the point of care.

Related publications

For more information, see the following publications:

  • Development and Validation of a Paper Spray Mass Spectrometry Method for the Rapid Quantitation of Remdesivir and its Active Metabolite, GS-441524, in Human Plasma. Christine Skaggs, Hannah Zimmerman, Nicholas Manicke, and Lindsey Kirkpatrick. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022.
  • Skaggs CL, Ren GJ, Shi R.Z., El Gierari ETM, Manicke NE and Kirkpatrick LM*: Simultaneous Quantitation of Five Triazole Anti-fungal Agents by Paper Spray-Mass Spectrometry. Clinical Chemistry and Laboratory Medicine. 58(5), 836-846 (2020).